June 19, 2025

Single Psilocybin Dose Yields Long-Term Cancer Relief

A single psilocybin dose combined with therapy led to lasting reductions in depression and anxiety for cancer patients two years after treatment, according to new research.

Conexiant

June 18, 2025

Medical Oddities: The Silver Lining in Loneliness

Loneliness flips the script—plus surprises from tea, tech, toxins, and a spicy twist.

Conexiant

June 18, 2025

Does Depression Predict Pain Later?

A long-term study of older adults found that symptoms of depression and loneliness began increasing years before the onset of pain and remained elevated afterward, especially in people with lower income or education levels.

Conexiant

June 16, 2025

Understanding Who Leaves Medical School—and Why

New research found higher rates of medical school attrition among lesbian, gay, or bisexual students, particularly those who are Hispanic, compared with their non-LGB peers.

Conexiant

June 11, 2025

Simvastatin Lowers Cholesterol—but Does Not Improve Depression Symptoms

A randomized trial of 160 adults with depression and obesity found no improvement in mood symptoms from adding simvastatin to escitalopram, though the statin significantly lowered cholesterol and inflammation levels.

Conexiant

June 05, 2025

Conservative Mental Health Study Faces Retraction

Scandinavian Journal of Psychology retracts study on conservatism and mental health, citing methodological flaws and biased language despite authors' objections.

Conexiant

June 05, 2025

Sister’s History Tied to 10-Fold Increase in Postpartum Psychosis Risk

A population-based study discussed at APAAM25 links full sibling history to increased risk of postpartum psychosis – but notes the absolute risk remains low.

Conexiant

June 04, 2025

Restrictive Eating Tied to Depression in Men

A UK study found that dietary restraint is linked to higher depressive symptoms, with stronger effects seen in men and individuals with elevated BMI.

Conexiant

June 02, 2025

PrEP Users With AUD Under-Treated, Study Finds

Researchers found that nearly 15% of commercially insured PrEP users had an alcohol use disorder diagnosis, yet fewer than 9% received FDA-approved treatment.

Conexiant